Bacterial Conjunctivitis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Bacterial Conjunctivitis – Pipeline Review, H2 2016’, provides an overview of the Bacterial Conjunctivitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis

The report reviews pipeline therapeutics for Bacterial Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bacterial Conjunctivitis therapeutics and enlists all their major and minor projects

The report assesses Bacterial Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bacterial Conjunctivitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bacterial Conjunctivitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bacterial Conjunctivitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

InSite Vision Incorporated

NovaBay Pharmaceuticals, Inc.

Shire Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Bacterial Conjunctivitis Overview 6

Therapeutics Development 7

Pipeline Products for Bacterial Conjunctivitis - Overview 7

Bacterial Conjunctivitis - Therapeutics under Development by Companies 8

Bacterial Conjunctivitis - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Bacterial Conjunctivitis - Products under Development by Companies 12

Bacterial Conjunctivitis - Companies Involved in Therapeutics Development 13

InSite Vision Incorporated 13

NovaBay Pharmaceuticals, Inc. 14

Shire Plc 15

Bacterial Conjunctivitis - Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Drug Profiles 24

auriclosene - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

azithromycin - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

ISV-405 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

SHP-640 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

vancomycin hydrochloride - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Bacterial Conjunctivitis - Dormant Projects 36

Bacterial Conjunctivitis - Product Development Milestones 37

Featured News & Press Releases 37

Jun 17, 2015: Manhattan U.S. Attorney Settles Civil Fraud Claims Against Inspire Pharmaceuticals For Its Misleading Marketing Designed To Cause Prescriptions Of Azasite For Non-Fda Approved Uses 37

Mar 17, 2015: InSite Vision Announces Settlement of Patent Infringement Lawsuit Against Mylan Pharmaceutical 38

Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US 38

Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops 38

Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops 39

Jun 17, 2013: InSite Vision Announces Joint Patent Infringement Lawsuit With Merck Against Mylan Pharma 39

Mar 26, 2013: InSite Vision Wins Appeal Of Patent Interference Litigation Against University Of California, San Francisco 39

Jan 05, 2012: University Of California, San Francisco Files Appeal Of USPTO Judgment In Favor Of InSite Vision 40

Nov 28, 2011: InSite Vision Wins Patent Interference Litigation Against University Of California, San Francisco 40

Dec 17, 2009: NovaBay To Receive Increase In Funding And Support From Alcon 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

List of Tables

Number of Products under Development for Bacterial Conjunctivitis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Bacterial Conjunctivitis – Pipeline by InSite Vision Incorporated, H2 2016 13

Bacterial Conjunctivitis – Pipeline by NovaBay Pharmaceuticals, Inc., H2 2016 14

Bacterial Conjunctivitis – Pipeline by Shire Plc, H2 2016 15

Assessment by Monotherapy Products, H2 2016 16

Number of Products by Stage and Target, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 23

Bacterial Conjunctivitis – Dormant Projects, H2 2016 36

List of Figures

List of Figures

Number of Products under Development for Bacterial Conjunctivitis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Assessment by Monotherapy Products, H2 2016 16

Number of Products by Targets, H2 2016 17

Number of Products by Stage and Targets, H2 2016 17

Number of Products by Mechanism of Actions, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Routes of Administration, H2 2016 21

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Stage and Molecule Types, H2 2016 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports